Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Aneesh Vijayan"'
Autor:
Lucy Rutten, Maarten Swart, Annemart Koornneef, Pascale Bouchier, Sven Blokland, Ava Sadi, Jarek Juraszek, Aneesh Vijayan, Sonja Schmit-Tillemans, Johan Verspuij, Ying Choi, Chenandly E. Daal, Aditya Perkasa, Shessy Torres Morales, Sebenzile K. Myeni, Marjolein Kikkert, Jeroen Tolboom, Daniëlle van Manen, Harmjan Kuipers, Hanneke Schuitemaker, Roland Zahn, Johannes P. M. Langedijk
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The spike protein (S) of SARS-CoV-2 induces neutralizing antibodies and is the key component of current COVID-19 vaccines. The most efficacious COVID-19 vaccines are genetically-encoded spikes with a double proline substitution in the hinge
Externí odkaz:
https://doaj.org/article/2c5d3e1e3a7e47e1962a95fc294bb57c
Autor:
Joan E. M. van der Lubbe, Sietske K. Rosendahl Huber, Aneesh Vijayan, Liesbeth Dekking, Ella van Huizen, Jessica Vreugdenhil, Ying Choi, Miranda R. M. Baert, Karin Feddes-de Boer, Ana Izquierdo Gil, Marjolein van Heerden, Tim J. Dalebout, Sebenzile K. Myeni, Marjolein Kikkert, Eric J. Snijder, Leon de Waal, Koert J. Stittelaar, Jeroen T. B. M. Tolboom, Jan Serroyen, Leacky Muchene, Leslie van der Fits, Lucy Rutten, Johannes P. M. Langedijk, Dan H. Barouch, Hanneke Schuitemaker, Roland C. Zahn, Frank Wegmann
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
Abstract Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human
Externí odkaz:
https://doaj.org/article/fc2cb2bea71d44b4a49590c0dc2b55f2
Autor:
Suresh C. Raman, Ernesto Mejías-Pérez, Carmen E. Gomez, Juan García-Arriaza, Beatriz Perdiguero, Aneesh Vijayan, Mar Pérez-Ruiz, Ana Cuervo, César Santiago, Carlos Oscar S. Sorzano, Cristina Sánchez-Corzo, Christiane Moog, Judith A. Burger, Anna Schorcht, Rogier W. Sanders, José L. Carrascosa, Mariano Esteban
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
There is an urgent need for the development of potent vaccination regimens that are able to induce specific T and B cell responses against human immunodeficiency virus type 1 (HIV-1). Here, we describe the generation and characterization of a fusion
Externí odkaz:
https://doaj.org/article/cd061f2f0dd048dba72f3844b70d364d
Autor:
Aneesh Vijayan, Juan García-Arriaza, Suresh C Raman, José Javier Conesa, Francisco Javier Chichón, César Santiago, Carlos Óscar S Sorzano, José L Carrascosa, Mariano Esteban
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0133595 (2015)
In the HIV vaccine field, there is a need to produce highly immunogenic forms of the Env protein with the capacity to trigger broad B and T-cell responses. Here, we report the generation and characterization of a chimeric HIV-1 gp120 protein (termed
Externí odkaz:
https://doaj.org/article/b225bef56f1c4bed90779626321815f0
Autor:
Dolores Rodríguez, Gloria González-Aseguinolaza, Juan R Rodríguez, Aneesh Vijayan, Magdalena Gherardi, Paloma Rueda, J Ignacio Casal, Mariano Esteban
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e34445 (2012)
With the aim to develop an efficient and cost-effective approach to control malaria, we have generated porcine parvovirus-like particles (PPV-VLPs) carrying the CD8(+) T cell epitope (SYVPSAEQI) of the circumsporozoite (CS) protein from Plasmodium yo
Externí odkaz:
https://doaj.org/article/6b4f3d58f46b4f218f18d9618786e713
Autor:
Alan G Goodman, Paul P Heinen, Susana Guerra, Aneesh Vijayan, Carlos Oscar S Sorzano, Carmen E Gomez, Mariano Esteban
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e25938 (2011)
There is a need to develop a universal vaccine against influenza virus infection to avoid developing new formulations of a seasonal vaccine each year. Many of the vaccine strategies for a universal vaccine target strain-conserved influenza virus prot
Externí odkaz:
https://doaj.org/article/8719081f2643411f8d187738fc19a7fd
Autor:
Lucy Rutten, Tim J. Dalebout, Liesbeth Dekking, Dan H. Barouch, Koert J. Stittelaar, Hanneke Schuitemaker, Frank Wegmann, Marjolein van Heerden, Joan E.M. van der Lubbe, Roland Zahn, Jessica Vreugdenhil, Sebenzile K. Myeni, Johannes P. M. Langedijk, Ella van Huizen, Miranda R.M. Baert, Leacky Muchene, Jan Serroyen, Marjolein Kikkert, Jeroen Tolboom, Ana Izquierdo Gil, Ying Choi, Sietske K. Rosendahl Huber, Karin Feddes-de Boer, Aneesh Vijayan, Leon de Waal, Eric J. Snijder, Leslie van der Fits
Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aebc400ef746539a4e9acf90c43787e1
https://doi.org/10.1101/2021.01.08.425915
https://doi.org/10.1101/2021.01.08.425915
Publikováno v:
Journal of Immunology
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2020, pp.ji2000746
Journal of Immunology, 2020, pp.ji2000746
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2020, pp.ji2000746
Journal of Immunology, 2020, pp.ji2000746
The TLR5 agonist flagellin is a potent adjuvant and is currently being developed for use in vaccines. The mechanisms that drive flagellin’s activity are influenced by its administration route. Previous studies showed that lung structural cells (esp
Autor:
Aneesh, Vijayan, Chetan E, Chitnis
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2013
The blood stage of the malaria parasite life cycle is responsible for all the clinical symptoms of malaria. During the blood stage, Plasmodium merozoites invade and multiply within host red blood cells (RBCs). Here, we review the progress made, chall
Autor:
Mar Pérez-Ruiz, Juan García-Arriaza, Carlos Oscar S. Sorzano, Christiane Moog, César Santiago, Rogier W. Sanders, Aneesh Vijayan, Mariano Esteban, Ernesto Mejías-Pérez, Ana Maria Cuervo, Cristina Sánchez-Corzo, Beatriz Perdiguero, Suresh C. Raman, José L. Carrascosa, Anna Schorcht, Judith A. Burger, Carmen E. Gómez
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, 2019, 10, ⟨10.3389/fimmu.2019.02793⟩
Frontiers in Immunology, Vol 10 (2019)
Frontiers in immunology, 10:2793. Frontiers Media S.A.
Digital.CSIC. Repositorio Institucional del CSIC
instname
Frontiers in Immunology, 2019, 10, ⟨10.3389/fimmu.2019.02793⟩
Frontiers in Immunology, Vol 10 (2019)
Frontiers in immunology, 10:2793. Frontiers Media S.A.
Digital.CSIC. Repositorio Institucional del CSIC
instname
There is an urgent need for the development of potent vaccination regimens that are able to induce specific T and B cell responses against human immunodeficiency virus type 1 (HIV-1). Here, we describe the generation and characterization of a fusion